Article Information
History
- April 28, 2022.
Article Versions
- You are currently viewing Version 1 of this article (April 28, 2022 - 14:12).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Mpho Tlalia,*,
- Andrew Scheibeb,c,d,
- Yann Ruffieuxe,
- Morna Cornella,
- Anja E Wettsteine,f,
- Matthias Eggera,e,g,
- Mary-Ann Daviesa,
- Gary Maartensh,
- Leigh F Johnsona and
- Andreas D Haase
- aCentre for Infectious Disease Epidemiology & Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
- bUrban Futures Centre, Steve Biko Campus, Durban University of Technology, Durban, South Africa
- cTB HIV Care, 7th Floor, 11 Adderley Street, Cape Town, South Africa
- dCommunity Oriented Primary Care Research Unit, Department of Family Medicine, University of Pretoria, Pretoria, South Africa
- eInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- fGraduate School of Health Sciences, University of Bern, Bern, Switzerland
- gPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- hDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- ↵*Corresponding author: Mpho Tlali, Centre for Infectious Disease Epidemiology & Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa, Tel: +27 (0)21 650 4550, E-mail: mpho.tlali{at}uct.ac.za
Posted April 28, 2022.
Diagnosis and treatment of opioid use disorder in a South African private sector medical insurance
